Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma
Mohamed E. Salem, Alberto Puccini, Joanne Xiu, et al.
The Oncologist (2018) Vol. 23, Iss. 11, pp. 1319-1327
Open Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, et al.
The Lancet (2021) Vol. 398, Iss. 10294, pp. 27-40
Open Access | Times Cited: 2056
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 11, pp. 1506-1517
Closed Access | Times Cited: 1009
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Claudio Luchini, Fréderic Bibeau, M. Ligtenberg, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1232-1243
Open Access | Times Cited: 820
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Yuichiro� Doki, Jaffer A. Ajani, Ken Kato, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 5, pp. 449-462
Open Access | Times Cited: 425
Gastric cancer treatment: recent progress and future perspectives
Wen‐Long Guan, Ye He, Rui‐Hua Xu
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 404
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade
Jianjun Yang, Xiguang Liu, Sai Cao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 143
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer
Harry H. Yoon, Zhaohui Jin, Oudom Kour, et al.
JAMA Oncology (2022) Vol. 8, Iss. 10, pp. 1456-1456
Open Access | Times Cited: 117
Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study
Jun Liu, Jingpei Li, Wanli Lin, et al.
International Journal of Cancer (2022) Vol. 151, Iss. 1, pp. 128-137
Open Access | Times Cited: 99
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 22
m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer
Huaying Zhao, Yue Xu, Yilin Xie, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 100
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
Tianshu Liu, Yuxian Bai, Xiaoyan Lin, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 4, pp. 749-760
Open Access | Times Cited: 55
Improving outcomes in patients with oesophageal cancer
Manish A. Shah, Nasser K. Altorki, Pretish Patel, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 6, pp. 390-407
Closed Access | Times Cited: 42
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial
Ken Kato, Yuichiro� Doki, Ian Chau, et al.
Cancer Medicine (2024) Vol. 13, Iss. 9
Open Access | Times Cited: 15
Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
Daniel Park, Won Jin Jeon, Chieh Yang, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 318-318
Open Access | Times Cited: 10
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Mathieu Larroquette, Charlotte Domblides, Félix Lefort, et al.
European Journal of Cancer (2021) Vol. 158, pp. 47-62
Open Access | Times Cited: 49
FADS2 function at the major cancer hotspot 11q13 locus alters fatty acid metabolism in cancer
Kumar S.D. Kothapalli, Hui Gyu Park, Niharika S.L. Kothapalli, et al.
Progress in Lipid Research (2023) Vol. 92, pp. 101242-101242
Open Access | Times Cited: 18
Investigating the causal role of the gut microbiota in esophageal cancer and its subtypes: a two-sample Mendelian randomization study
Jia Li, Xuedi Gao, Xiaoming Sun, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 8
SIRT2‐mediated deacetylation of ACLY promotes the progression of oesophageal squamous cell carcinoma
Xueying Zhang, Yue Xu, Shenglei Li, et al.
Journal of Cellular and Molecular Medicine (2024) Vol. 28, Iss. 6
Open Access | Times Cited: 7
BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation
Peipei Zhang, Weiguang Zhang, Xiaoqing Wang, et al.
Cancer Letters (2024) Vol. 591, pp. 216874-216874
Closed Access | Times Cited: 7
Specific DNA methylation markers in the diagnosis and prognosis of esophageal cancer
Dapeng Li, Lei Zhang, Yupeng Liu, et al.
Aging (2019) Vol. 11, Iss. 23, pp. 11640-11658
Open Access | Times Cited: 47
FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
Csongor György Lengyel, Sadaqat Hussain, Andreas Seeber, et al.
Life (2022) Vol. 12, Iss. 1, pp. 81-81
Open Access | Times Cited: 23
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
Markus Moehler, Hong Xiao, Steven I. Blum, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 35, pp. 5388-5399
Open Access | Times Cited: 15
Immune checkpoint inhibitors versus chemotherapy as second-line therapy for advanced oesophageal squamous cell carcinoma: a systematic review and economic evaluation
Shixian Liu, Lei Dou, Shunping Li
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 6
Precision medicine for gastrointestinal cancer: Recent progress and future perspective
Tasuku Matsuoka, Masakazu Yashiro
World Journal of Gastrointestinal Oncology (2019) Vol. 12, Iss. 1, pp. 1-20
Open Access | Times Cited: 40
Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer
Rachel Sexton, Zaid Mahdi, Rahman Chaudhury, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 19, pp. 4826-4826
Open Access | Times Cited: 36
Page 1 - Next Page

Scroll to top